Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) Equity Ratio (2022 - 2025)

Historic Equity Ratio for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to 0.69.

  • Taysha Gene Therapies' Equity Ratio rose 4040.16% to 0.69 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.69, marking a year-over-year increase of 4040.16%. This contributed to the annual value of 0.45 for FY2024, which is 280.75% up from last year.
  • According to the latest figures from Q3 2025, Taysha Gene Therapies' Equity Ratio is 0.69, which was up 4040.16% from 0.75 recorded in Q2 2025.
  • Over the past 5 years, Taysha Gene Therapies' Equity Ratio peaked at 0.75 during Q2 2025, and registered a low of 0.46 during Q2 2023.
  • Over the past 4 years, Taysha Gene Therapies' median Equity Ratio value was 0.35 (recorded in 2024), while the average stood at 0.26.
  • The largest annual percentage gain for Taysha Gene Therapies' Equity Ratio in the last 5 years was 567272.17% (2023), contrasted with its biggest fall of 36127.99% (2023).
  • Over the past 4 years, Taysha Gene Therapies' Equity Ratio (Quarter) stood at 0.01 in 2022, then skyrocketed by 5672.72% to 0.43 in 2023, then grew by 2.81% to 0.45 in 2024, then surged by 55.1% to 0.69 in 2025.
  • Its Equity Ratio stands at 0.69 for Q3 2025, versus 0.75 for Q2 2025 and 0.4 for Q1 2025.